Every pharma marketer in the MENA region has heard some version of this: "We'd love to do that campaign, but compliance won't let us." More often than not, the issue is not the regulator — it is the operating model. Brands that treat compliance as a late-stage gate spend twice as long getting to market and ship weaker creative when they get there.
This is a practical primer on the regulatory landscape that governs pharma marketing in Saudi Arabia and the UAE, and how the best brands are designing around it.
Questions answered (6)
Saudi Arabia: SFDA and MoH?
The Saudi Food and Drug Authority (SFDA) is the primary regulator for pharmaceutical promotion in the Kingdom. Its guidelines cover what can be said, to whom, and through which channels. Promotional content directed at HCPs must be balanced, evidence-based, and consistent with the locally approved label.
Key practical implications:
- All promotional materials, including digital assets, require pre-approval
- Adverse event reporting workflows must be embedded in every interactive channel
- Direct-to-consumer promotion of prescription medicines is not permitted
- Disease awareness campaigns are allowed but must be unbranded and educational
Layered on top is the Personal Data Protection Law (PDPL), which governs how HCP and patient data is collected, stored and processed — including data residency considerations.
United Arab Emirates: MoHAP, DHA and DoH?
The UAE has a federal regulator (MoHAP) and emirate-level authorities (DHA in Dubai, DoH in Abu Dhabi). Each has its own promotional code, with overlapping but not identical requirements. CME accreditation in particular varies by emirate, which matters for any educational content strategy.
The UAE PDPL adds an additional consent and data-handling layer for any campaign that touches HCP or patient data.
Designing a compliance-first operating model?
The brands shipping compliant campaigns fastest in the region share four habits:
- Medical, legal and regulatory (MLR) reviewers are embedded in the campaign team from kickoff, not parachuted in at the end
- Modular content architecture — claims, references and visuals are approved as reusable atoms, not as monolithic decks
- Channel-specific compliance playbooks (WhatsApp, webinars, social, programmatic) so creative teams know the guardrails before they brief
A single source of truth for approved claims, references and visuals across markets?
Why this matters competitively?
Compliance is often framed as a cost. In MENA right now, it is a competitive advantage. The brands that have industrialized their MLR process can ship 3-5x more approved content per quarter than their peers — which translates directly into share of voice across HCP channels.
The takeaway?
If compliance feels like the slowest part of your campaign cycle in KSA or the UAE, the fix is almost never "push the regulator harder". It is to redesign the operating model so compliance is a parallel workstream, not a final gate.
Have a question we did not cover?
Talk to our team about HCP engagement, experiential and digital strategy across the GCC.
Ask our team
